m7Gpp

The Uses of m7Gpp

m7Gpp is an important intermediate for the synthesis of mRNA cap analogs.

Clinical claims and research

mRNA Cap analogs has the highest cost in all raw materails of mRNA vaccine. Like modified GAG, mofied GGG, etc. the synthetic steps are more than 18 operations. The total prorcess field is less than 15%. How to cut the cost of mRNA Cap analogs is the significant job for the mRNA commerial production.

Current market and forecast

Recent developments in mRNA cap analogs highlight the importance of mRNA as a powerful tool for studying RNA metabolism and uncover the potential of targeted mRNAs for cancer treatment, gene therapy, antiviral therapy and improved targeting of nuclease-targeted drugs.
Chemically modified mRNA cap analogs consist of the unique cap structure m7G [5'] ppp [5'] N (where N = G, A, C or U) and are present in many eukaryotic and viral 5' end RNAs and several non-coding RNAs. the presence of sugar substitutions on the m7G portion of the cap analog has a significant impact on the orientation, translation efficiency, binding affinity and nature of nuclear stability.
The synthesis of various cap analogs with 7-methylguanosine (m7G) sugar substitution modifications is a rather complex organic synthesis, usually with more than 18 reaction steps, using reagents and raw materials not readily available, such as 3'-propynyl, 2', 3'-isopropylidene, 2', 3'-diacetyl and 2' -amino, triphosphate bridging, e.g. iminodiphosphate and methylenebis(phosphonate); triphosphate non-bridging, e.g., BH3, Se and S; and nucleobase substitutions, e.g., 6-thioguanosine and triazole.